Compare · EXEL vs WWB
EXEL vs WWB
Side-by-side comparison of Exelixis Inc. (EXEL) and Windward Bio Group AG (WWB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EXEL and WWB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- EXEL is the larger of the two at $16.66B, about 12.4x WWB ($1.35B).
- WWB has been more active in the news (14 items in the past 4 weeks vs 7 for EXEL).
- EXEL has more recent analyst coverage (25 ratings vs 0 for WWB).
- Company
- Exelixis Inc.
- Windward Bio Group AG
- Price
- -
- -
- Market cap
- $16.66B
- $1.35B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2026
- News (4w)
- 7
- 14
- Recent ratings
- 25
- 0
Exelixis Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Windward Bio Group AG
Windward Bio Group is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. Our product candidates, WIN378 and WIN027, target clinically validated disease pathways and are engineered to remain in the body for extended periods of time, enabling less frequent dosing than currently available treatments. This design feature is combined with additional properties including enhanced target affinity, dual target binding or effector function silencing. We believe our product candidates have the potential to deliver better clinical outcomes while offering the convenience of less frequent dosing than currently available treatments.
Latest EXEL
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- SEC Form SCHEDULE 13G filed by Exelixis Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Exelixis Inc.
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
- SEC Form 10-Q filed by Exelixis Inc.
- SEC Form 8-K filed by Exelixis Inc.
- Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
- Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Exelixis Inc. filed SEC Form 8-K: Other Events
Latest WWB
- Director David P Bonita bought $20,000,007 worth of shares (1,176,471 units at $17.00), converted options into 5,172,944 shares, exercised 216,668 shares at a strike of $0.02 and covered exercise/tax liability with 232 shares (SEC Form 4)
- Director Orbimed Advisors Llc bought $20,000,007 worth of shares (1,176,471 units at $17.00), converted options into 5,172,944 shares, exercised 216,668 shares at a strike of $0.02 and covered exercise/tax liability with 232 shares (SEC Form 4)
- Director Otello Stampacchia bought $29,750,000 worth of shares (1,750,000 units at $17.00) and converted options into 3,588,520 shares (SEC Form 4)
- Windward Bio to Participate at the Jefferies London Global Healthcare Conference
- Director Mufti Iqbal Rasool was granted 22,675 share options (SEC Form 4)
- Chief Operating Officer Harris Kevin Andrew was granted 33,206 shares, increasing direct ownership by 4% to 960,966 units (SEC Form 4)
- Chief Executive Officer Santarelli Luca was granted 815,755 employee share options (SEC Form 4)
- Chief Financial Officer D'Augusta Claudia was granted 180,160 employee share options (SEC Form 4)
- Director Bonita David P was granted 22,675 stock options (SEC Form 4)
- Director Stampacchia Otello was granted 22,675 share options (SEC Form 4)